Brief: Regen Biopharma restructures management stock compensation
15/03/2017 12:00
March 15 (Reuters) - Regen Biopharma Inc RGBP.OB
* Regen Biopharma restructures management stock compensation
* Management team has agreed to collectively cancel 16.5
million common shares and 15 million series a preferred shares
* Company has created a new class of stock, series M
preferred which does not trade publicly
* Management team will receive replacement shares for
publicly traded shares they cancelled
Source text for Eikon: ID:nPn8tswLZa
Further company coverage: RGBP.OB
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Regen BioPharma
See all newsBrief: Regen Biopharma Prepares Response For FDA Regarding Its Orphan Drug Application For HemaXellerate
Brief: Regen Biopharma Expands Vision For Phase 1 Clinical Trial Of Hemaxellerate
Brief: Regen Biopharma, Inc. Receives First Phase Of Confirmatory Study
Brief: Regen Biopharma Files Provisional Patent On Car-T Cell Capable Of Attracting And Educating Naïve T Cells
Brief: Regen Biopharma addresses potential impact of recent Bristol Myers Squibb's $2.3 billion acquisition of IFM Therapeutics